A porcine model to study the effect of brain death on kidney genomic responses

Mitchell B. Sally1,2*, Darren J. Malinoski1,2, Frank P. Zaldivar3, Tony Le4, Matin Khoshnev5, William A. Pinette6, Michael Hutchens1 and Shlomit Radom-Aizik3

1 Operative Care Division, Section of Surgical Critical Care, VA Portland Health Care System, Portland, OR, USA
2 Department of Surgery, Division of Trauma, Critical Care, and Acute Care Surgery, Oregon Health and Science University, Portland, OR, USA
3 Department of Pediatrics, Pediatric Exercise and Genomics Research Center (PERC), University of California at Irvine, Irvine, CA, USA
4 Department of Family Medicine, Naval Hospital, Jacksonville, FL, USA
5 Department of Ophthalmology, Temple University, Philadelphia, PA, USA
6 Department of Surgery, Wright State University, Dayton, OH, USA

Introduction. A majority of transplanted organs come from donors after brain death (BD). Renal grafts from these donors have higher delayed graft function and lower long-term survival rates compared to living donors. We designed a novel porcine BD model to better delineate the incompletely understood inflammatory response to BD, hypothesizing that adhesion molecule pathways would be upregulated in BD.

Methods. Animals were anesthetized and instrumented with monitors and a balloon catheter, then randomized to control and BD groups. BD was induced by inflating the balloon catheter and animals were maintained for 6 hours. RNA was extracted from kidneys, and gene expression pattern was determined.

Results. In total, 902 gene pairs were differently expressed between groups. Eleven selected pathways were upregulated after BD, including cell adhesion molecules.

Conclusions. These results should be confirmed in human organ donors. Treatment strategies should target involved pathways and lessen the negative effects of BD on transplantable organs.
observed at increased levels in humans and animals after receiving an organ from a DBD [8–10]. Increases in these circulating and tissue mediators in the recipient have been shown to be associated with poor graft outcomes in heart, liver, and renal transplants [11–16]. These studies have looked at small animal models, examined circulating or tissue protein levels in the recipient after transplantation, and focused on donor tissue after prolonged periods of warm and cold ischemia. None have focused on both a larger, more translationally relevant animal model and gene expression levels in the DBD before organ recovery. It is essential to better understand the state of potentially transplantable organs at the time of organ recovery, as this is when decisions are being made by transplant programs about the suitability of organs for transplantation. Combining these 2 approaches is necessary to inform potential human organ donor interventions aimed at increasing the availability of organs suitable for transplantation, as there may be targets for intervention identified in the donor.

Kidney transplantation is a common research target, since kidneys are the most frequently donated organs, and because obtaining biopsy data is a common practice. Further, delayed graft DGF, defined as a recipient needing hemodialysis within the 1st week after transplant, provides a short-term surrogate outcome for measuring graft success. What remains incompletely understood is how the cellular and molecular processes behind BD and its inflammatory response contribute to poor graft function and survival from DBDs. Previous research has shown that deceased organ donor kidney gene expression patterns are different than living donor specimens [17], however, this work was performed after cold storage and was also limited by small sample size. The objective for our study was to better delineate the inflammatory response to herniation in the kidney using gene expression microarray technology to identify specific gene pathways that are altered before cold storage and transplantation. This study would be the first kidney-specific porcine model examining early changes in gene expression and gene pathways, and begins to provide correlative data for the inflammatory response to BD. Identification of specific inflammatory gene pathways could lead to future characterization of diagnostic biomarkers for organ quality, as well as the development of potential therapeutic interventions to improve graft function and survival. Based on their relevance to the cell-mediated immune response and transplantation, we hypothesized that cell adhesion molecule pathways involved in inflammation will be altered in the kidney following brainstem herniation.

Materials and Methods

Porcine Model of Brain Death

The animal protocols used in this study were approved by the UCI institutional animal care and use committee (UCI-IACUC). In total, 20 domestic female Chesterwhite or Yorkshire swine at 6 weeks of age were purchased from S&S Farms in San Diego County, CA. Animals (20–30 kg) were acclimated for 72 hours, fasted for 12 hours, and induced with an intramuscular combination of ketamine (21 mg/kg), xylazine (2.2 mg/kg), and atropine (0.04 mg/kg). Pentothal (10 mg/kg) was then given intravenously for induction via an ear vein catheter and endotracheal intubation was performed. Ventilation and anesthesia were maintained with isoflurane (0.75%–4%). Electrocardiogram leads, pulse oximetry, and end-tidal carbon dioxide (CO₂) were monitored and adequate anesthesia was confirmed by assessing jaw tone, movement, and vital signs. Femoral artery and external jugular catheters were placed for hemodynamic monitoring, blood collection, and fluid administration. Based on a previously described model [18], a left-sided parietal burr hole was created, and a 15 cc epidural balloon catheter and subdural intracranial pressure (ICP) monitor were placed through this access point. A subdural laser Doppler flow probe was placed in the right frontal area (Fig. 1). After a 30-minute rest period, a physiologic baseline was established and brainstem herniation was induced by inflating the 15-cc balloon catheter over 1 min, mimicking the effects of a space-occupying lesion and eventual herniation. The balloon remained inflated for 20 minutes, then was deflated. Herniation was evaluated with a contralateral laser Doppler flow probe and an ipsilateral ICP catheter. BD was defined as a drop in blood flow to <15% of baseline, ICP persistently greater than mean arterial pressure (MAP), and fixed and dilated pupils [18]. BD was also verified in the first two animals in the BD group using conventional apnea testing in order to validate the previous model upon which our study was based [18]. Apnea testing was performed after preoxygenation with 100% oxygen for 5 minutes, followed by disconnecting the ventilator. Base-line levels of pCO₂ were measured. After 10 minutes of being disconnected from the ventilator, another level of pCO₂ was measured before placing the animal back on mechanical ventilation. If there was an increase of 20 mmHg pCO₂ compared with baseline, BD was confirmed, consistent with national guidelines.

In total, 20 animals were randomized into 2 groups: a control group (burr hole, catheters, and anesthesia only) and a BD group (instrumentation plus inflation of subdural balloon catheter and confirmation of BD). Animals were supported on mechanical ventilation for 6 hours after randomization and 2 cc/kg boluses of 0.9% NaCl were given as needed to maintain a MAP above 35 mmHg to prevent cardiovascular collapse. Vasopressors were not utilized, consistent with the validated model upon which our study was based. Both groups were maintained with isoflurane for the duration of the case. A laparotomy was then performed and kidney specimens were obtained and snap frozen.

Vital signs were recorded every minute during the balloon inflation phase and at regular intervals during the 6-hour maintenance phase. Repeated measures ANOVA statistics were used to analyze mean physiologic variables and determine difference between groups during the balloon inflation phase and an independent-samples t-tests was used to analyze terminal values for ICP, MAP, and HR.

RNA Extraction

Total RNA for gene expression analysis was extracted from the porcine kidney tissue using TRIzol® (Gibco BRL Life Technologies, Rockville, MD, USA). RNA was purified using Qiagen-RNasey Mini Kit.
Arrays were scanned using GeneChip® Scanner 3000 7G and Command Console Software v 3.2.3. to produce .CEL intensity files by ANOVA testing.

**Gene Expression Microarrays**

Microarray processing was performed as recommended by the manufacturer and is available in the Affymetrix GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, CA, USA). In brief, first-strand cDNA was synthesized from 250 ng of total RNA. After making the complementary second strand, the double-stranded cDNA is used to generate biotin-tagged cRNA from an in-vitro transcription using T7 RNA polymerase. Ten μg of fragmented target cRNA was hybridized on an Affymetrix GeneChip® Porcine Genome Array. Arrays were scanned using GeneChip® Scanner 3000 7G and Command Console Software v 3.2.3. to produce .CEL intensity files.

**Gene Expression Data Analysis**

The results were analyzed using GeneSpring GX 12.1 Software (Agilent Technologies, Inc.). Raw data were normalized using GC-RMA. Only probe sets that reached a signal value ≥50 in at least 50% of the values in anyone out of the 2 conditions were included in the analysis. Overall, 17,566 of 54,675 probe sets represented on the array met these criteria. The microarray cell files and GC-RMA normalized data have been deposited in the GEO database (series accession number https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94709). Traditional Student’s paired t-test was first applied to each probe set and fold change (increase or decrease) >1.5 and Multiple Testing Correction (false discovery rate [FDR] <0.05) (Benjamini–Hochberg) procedure was carried out for statistical analysis.

The final list of significantly different expression probe sets between the 2 groups was then additionally analyzed using the functional annotation tools provided by DAVID 6.8, the Database for Annotation, Visualization and Integrated Discovery to classify the genes into pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Only pathways with Expression Analysis Systematic Explorer (EASE) score ≤0.05 are presented in this analysis. The EASE score is a modified Fisher exact p value in the DAVID system used for gene-enrichment analysis. An EASE score p value = 0 represents perfect enrichment. p value ≤ 0.05 is considered as gene enrichment in a specific annotation category (http://david.abcc.ncifcrf.gov/helps/functional_annotation.html#summary).

**Microarray Results Corroboration Using RT-PCR**

For confirmation of gene expression microarray findings, reverse transcriptase polymerase-chain reaction (RT-PCR) assays were carried out on 6 genes from the KEGG cell adhesion pathway (SLA-DRA, SLA-1, SLA-DQA, ITGB2, ITGB8, and VCAM1). Analysis was performed with the Applied Biosystems 7900HT PCR System by using TaqMan Universal PCR Master Mix and Assays-on-Demand Gene Expression probes (Applied Biosystems) (SLA-DRA: assay ID, Ss03389945_m1; ITGB2: assay ID, Ss03392626_u; ITGB8: assay ID, Ss03385280_g1; and SLA-1: Ss03395429_s1; SLA-DQA: Ss03389954_g1; VCAM1: assay ID, Ss03390914_m1). Actin βi was used as an endogenous control.

**Results**

**Animal Model**

In total, 10 animals were assigned to the BD group and 10 animals were assigned to the control group. One animal in the BD group and 2 animals in the control group were unable to be maintained for 6 hours under general anesthesia and suffered cardiac arrest; upon autopsy, it was discovered that these animals had pre-existing illnesses.

Hemodynamic and intracranial physiologic results during the balloon inflation phase are displayed in Fig. 2. All animals in the experimental group and none in the control group met criteria for BD. Animals in BD and control groups had similar physiologic variables at initiation of general anesthesia: control animals had a mean heart rate (HR) of 80.3 ± 18.4 beats per minute (BPM) and experimental animals had a mean HR of 85.1 ± 9.0 BPM (p = 0.49); MAP at induction was 64.6 ± 11.6 mm of mercury (mmHg) for control animals and 68.7 ± 11.0 mmHg for experimental animals (p = 0.47); and ICP at induction was 17.3 ± 5.5 mmHg for control animals and 16.8 ± 7.3 mmHg for experimental animals (p = 0.88).

The expected catecholamine surge associated with herniation was demonstrated in the animals in the BD group during the time of balloon inflation. Initially, HR and MAP increased dramatically to a highest mean HR of 125.3 ± 30.8 BPM at 4 minutes after balloon inflation and a highest MAP of 106.1 ± 16.9 mmHg at 3 minutes postinflation. Means were compared using repeated measures ANOVA, and significant differences were found for MAP at minutes 2–6 and for HR at minutes 3–5 (Fig. 2) during balloon inflation are displayed in Fig. 2. At the conclusion of the balloon inflation phase, there were no significant differences between the groups with regard to HR or MAP (Fig. 2).

After maintenance of 6 hours of general anesthesia, the terminal ICP values were significantly different between control and experimental groups (19.3 ± 4.5 vs. 59.3 ± 18.8, p < 0.001), however mean MAP (59.7 ± 17.1 vs. 56.9 ± 13.8, p = 0.73) and HR (85 ± 19.3 vs. 122.3 ± 43.8, p = 0.06) between groups were not significant.

**The Effects of BD on Kidney Gene Expression**

Using FDR <0.05 with 95% confidence, a total of 902 probe sets were differentially expressed between BD and control group which...
represent 233 annotated genes. In total, 139 genes had higher expression in the BD compared with control, and 94 genes had lower expression in the BD compared to control (online Supplementary Table 1).

We classified the final list of genes with significantly different expression between the 2 groups into pathways using the KEGG database. In total, 40 pathways (EASE score ≤ 0.01, FDR < 0.05) were enriched with genes that expressed significantly different between the 2 groups.

Table 1 presents 11 selected pathways linked to the immune response, cell communication, allograft rejection, and graft-versus-host disease. Table 2 presents the individual upregulated genes within our primary pathway of interest, cell adhesion molecules, and the degree of fold change associated with the upregulation. Fig. 3 is a diagrammatic representation of the KEGG pathway for the cell adhesion molecules.

### Table 1. Selected Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in porcine model significantly upregulated 6 hours following brainstem herniation when compared with control animals

| KEGG pathway                        | Number of genes | EASE score | FDR     | Role in inflammation and transplantation                                      |
|-------------------------------------|-----------------|------------|---------|--------------------------------------------------------------------------------|
| Antigen processing and presentation | 7               | 7.20E-05   | 7.60E-04| Associated with macrophage presence in rejected renal allograft specimens [19] |
| Toll-like receptor signaling pathway | 8               | 1.00E-04   | 1.00E-03| Initiate allograft inflammation and promote development of acute and chronic rejection [20] |
| TNF-signalization pathway           | 8               | 1.50E-04   | 1.40E-03| Inhibition protects kidney from ischemia-reperfusion injury by reducing accumulation of macrophages/monocytes [21] |
| Graft-versus-host disease           | 5               | 4.60E-04   | 4.00E-03| Associated with immune function, chronic inflammation [22]                        |
| Allograft rejection                 | 5               | 6.40E-04   | 4.40E-03| Upregulated renal dysfunction in transplant recipients [23]                         |
| Cell adhesion molecules (CAMs)      | 8               | 8.50E-04   | 5.40E-03| Mediate infiltration to graft, disseminate antigenic message to host lymphoid tissue [24] |
| Natural killer cell-mediated cytotoxicity | 7              | 1.00E-03   | 5.90E-03| Play a role in renal transplant loss [25]                                           |
| Cytokine-cytokine receptor interaction | 9              | 2.60E-03   | 1.20E-02| Upregulated in renal dysfunction in transplant recipient [23]                       |
| Jak-STAT signaling pathway          | 7               | 4.00E-03   | 1.80E-02| Upregulated in renal dysfunction in transplant recipients [23]                       |
| PPAR signaling pathway              | 5               | 5.80E-03   | 2.50E-02| Postulated involvement in UC after renal transplant [26]                           |
| Chemokine signaling pathway         | 7               | 1.00E-02   | 2.40E-02| Upregulated in inflammatory states like SCI [27]                                   |

In this diagram, the various genes and their interactions are displayed and those upregulated after BD in our animal model are noted.

RT-PCR was performed to corroborate the microarray results in our primary outcome of interest, the cell adhesion molecule pathway. A total of 6 representative genes were upregulated, 5 of which were noted to be significant (p < 0.05) (Table 3).

### DISCUSSION

Efforts are needed to improve the quantity and quality of organs available for transplantation, and a better understanding of the inflammatory response to brainstem herniation may help to identify targets for future therapeutic interventions. Toward that end, we examined the genomic response to herniation in the porcine kidney and found significant differences in the expression levels of 233 genes, which were classified into gene pathways. These affected pathways play a central role in inflammation, allograft rejection, antigen processing and presentation, Toll-like receptor signaling, tumor necrosis factor (TNF) signaling, graft-versus-host disease, cell adhesion molecules, natural killer cell-mediated toxicity, Janus kinase/signal transducers and activators of transcription (Jak-STAT) signaling, peroxisome proliferator-activated receptor signaling, and chemokine signaling. Additionally, the results confirmed our hypothesis that adhesion molecule pathways are significantly upregulated after brainstem herniation and BD.

It has been established that a cascade of events result from severe neurologic injuries and brainstem herniation. This cascade usually begins with activation of the parasympathetic pathway, leading to hypotension, hypotension, and electrolyte disturbances. This derangement is then followed by sympathetic stimulation, resulting in high catecholamine release, tachycardia, and hypertension [10]. Though this response to BD is well described in the literature, there is a dearth of information concerning the inflammatory response to brainstem herniation at the genetic level.

In reviewing the genetic contribution to organ transplantation after BD, both existing genotypes and regulation of these genotypes, or epigenetic events, should be examined. Several groups have examined the idea that certain genetic makeups are predictive of success in transplantation. One early study, limited by sample size, was unable to show any association between donor single-nucleotide polymorphisms and DGF [28]. However, subsequent studies have shown that differences in TNF-α and TGF-β gene polymorphisms between donor and recipient were associated with increased acute rejection [29, 30]. The fact that genetic polymorphisms are associated with differential rejection rates suggests that examining downstream gene expression patterns may increase our understanding of BD and how it affects transplantation outcomes.

In addition to polymorphisms that may contribute to graft function, gene pathways that are affected during the process of BD have been described in the literature. However, these previous genomic studies have been performed on tissue immediately prior to implantation, after prolonged periods of both warm and cold ischemia. In our model, we examine the effects of BD on the genomic pathways in the donor, prior to any period of ischemia, cold storage, or interaction with the recipient immune response. With respect to the pre-implantation literature, several groups have examined apoptotic pathway, and DGF has been shown to correlate with increased expression in biopsies obtained after cold storage [31]. Confounding these results is that fact that longer durations of CIT have been shown to increase apoptosis expression in specimens from DBDs [7]. In another study, higher pre-implant lipocalin 2 (LCN-2) expression correlated with increased DGF rates and acute rejection episodes [32]. In an effort to avoid alterations in gene expression patterns that cold ischemia may induce, our animal model focuses on tissue specimens obtained at the time of organ
| Pathway                                                                 | Gene name (gene symbol) | FC  | Directional change |
|------------------------------------------------------------------------|-------------------------|-----|--------------------|
| Antigen processing and presentation                                     |                         |     |                    |
| MHC class II DR-α (SLA-DRA)                                             | 1.6                     | Up  |                    |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1)              | 1.8                     | Up  |                    |
| SLA-DQ β1 domain (SLA-DQB1)                                             | 1.6                     | Up  |                    |
| Major histocompatibility complex, class II, DO α (SLA-DOA)             | 1.8                     | Up  |                    |
| Proteasome activator subunit 2 (PSME2)                                 | 1.7                     | Up  |                    |
| Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (TAP1)    | 2.2                     | Up  |                    |
| Toll-like receptor signaling pathway                                    |                         |     |                    |
| FBJ murine osteosarcoma viral oncogene homolog (FOS)                   | 3.3                     | Up  |                    |
| Caspase 8, apoptosis-related cysteine peptidase (CASP8)                | 1.8                     | Up  |                    |
| Chemokine (C-C motif) ligand 4 (CCL4)                                  | 2.4                     | Up  |                    |
| Chemokine (C-C motif) ligand 5 (CCL5)                                  | 2.7                     | Up  |                    |
| Interferon (α, β, and ω) receptor 1 (IFNAR1)                           | 1.8                     | Up  |                    |
| Interferon regulatory factor 7 (IRF7)                                   | 2.1                     | Up  |                    |
| Signal transducer and activator of transcription 1, 91 kDa (STAT1)    | 1.9                     | Up  |                    |
| Toll-like receptor-4 (TLR-4)                                           | 1.9                     | Up  |                    |
| TNF signaling pathway                                                  |                         |     |                    |
| FBJ murine osteosarcoma viral oncogene homolog (FOS)                   | 3.3                     | Up  |                    |
| Activating transcription factor 4 (ATF4)                               | 1.6                     | Up  |                    |
| Caspase 3, apoptosis-related cysteine peptidase (CASP3)                | 1.5                     | Up  |                    |
| Caspase 8, apoptosis-related cysteine peptidase (CASP8)                | 1.8                     | Up  |                    |
| Chemokine (C-C motif) ligand 2 (CCL2)                                  | 14.3                    | Up  |                    |
| Chemokine (C-C motif) ligand 5 (CCL5)                                  | 2.7                     | Up  |                    |
| Ribosomal protein S6 kinase α-5 (LOC100152046)                         | 3.3                     | Up  |                    |
| Vascular cell adhesion molecule 1 (VCAM1)                              |                         |     |                    |
| Graft-versus-host disease                                              |                         |     |                    |
| MHC class I antigen 1 (SLA-1)                                          | 1.6                     | Up  |                    |
| MHC class II DR-α (SLA-DRA)                                            | 1.6                     | Up  |                    |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1)             | 1.8                     | Up  |                    |
| SLA-DQ β1 domain (SLA-DQB1)                                            | 1.6                     | Up  |                    |
| Major histocompatibility complex, class II, DO α (SLA-DOA)             | 1.8                     | Up  |                    |
| Allograft rejection                                                     |                         |     |                    |
| MHC class I antigen 1 (SLA-1)                                          | 1.6                     | Up  |                    |
| MHC class II DR-α (SLA-DRA)                                            | 1.6                     | Up  |                    |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1)             | 1.8                     | Up  |                    |
| SLA-DQ β1 domain (SLA-DQB1)                                            | 1.6                     | Up  |                    |
| Major histocompatibility complex, class II, DO α (SLA-DOA)             | 1.8                     | Up  |                    |
| Cell adhesion molecules (CAMs)                                         |                         |     |                    |
| MHC class I antigen 1 (SLA-1)                                          | 1.6                     | Up  |                    |
| MHC class II DR-α (SLA-DRA)                                            | 1.6                     | Up  |                    |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1)             | 1.8                     | Up  |                    |
| SLA-DQ β1 domain (SLA-DQB1)                                            | 1.6                     | Up  |                    |
| Major histocompatibility complex, class II, DO α (SLA-DOA)             | 1.8                     | Up  |                    |
| Vascular cell adhesion molecule 1 (VCAM1)                              | 3.3                     | Up  |                    |
| Natural killer cell-mediated cytotoxicity                               |                         |     |                    |
| FYN proto-oncogene, Src family tyrosine kinase (FYN)                   | 1.9                     | Up  |                    |
| Fc fragment of IgG, low affinity IIb, receptor (CD16b) (FCGR3B)        | 2.0                     | Up  |                    |
| TYRO protein tyrosine kinase binding protein (TYROBP)                  | 1.6                     | Up  |                    |
| Caspase 3, apoptosis-related cysteine peptidase (CASP3)                | 1.5                     | Up  |                    |
| Integrin, β2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 1.8                     | Up  |                    |
| Integrin, β8 (ITGB8)                                                  | 2.7                     | Up  |                    |
| Major histocompatibility complex, class II, DO α (SLA-DOA)             | 1.8                     | Up  |                    |
| Vascular cell adhesion molecule 1 (VCAM1)                              | 3.3                     | Up  |                    |
| Cytokine-cytokine receptor interaction                                 |                         |     |                    |
| Bone morphogenetic protein receptor, type IB (BMPR1B)                  | 14.3                    | Up  |                    |
| Chemokine (C-C motif) ligand 2 (CCL2)                                  | 2.4                     | Up  |                    |
| Chemokine (C-C motif) ligand 4 (CCL4)                                  | 2.4                     | Up  |                    |
| Chemokine (C-C motif) ligand 5 (CCL5)                                  | 2.7                     | Up  |                    |
| Protein tyrosine phosphatase, nonreceptor type 6 (PTPN6)               | 1.7                     | Up  |                    |
| Transforming growth factor, β 1 (TGFβ1)                                | 2.0                     | Up  |                    |
recovery, prior to cold preservation, to isolate those pathways strictly related to the process of brainstem herniation that could be targets for intervention during organ donor management.

Many of the described studies have been performed in mice or rats, which have poor genetic correlation with human pathways [33]. Due to both greater genetic and anatomic similarities with humans, swine are one of the most commonly used species in biomedical translational research models. In 2012, Hume et al. published the first porcine genome-wide transcriptional analysis that included 62 tissues and cell types, providing an important resource for understanding the relationship between porcine and human gene expression [34]. In one of the first porcine models of brainstem herniation, Mclean et al. examined the effect of glucocorticoid administration on circulating levels of

| **Table 2. Continued** |
|------------------------|
| **Gene name (gene symbol)** | **FC** | **Directional change** |
| **Jak-STAT signaling pathway** | | |
| Janus kinase 2 (JAK2) | 2.0 | Up |
| Growth hormone receptor (GHR) | 2.2 | Down |
| Interferon (α, β, and ω) receptor 1 (IFNAR1) | 1.8 | Up |
| Interleukin 10 receptor, β (IL10RB) | 2.7 | Up |
| Protein tyrosine phosphatase, nonreceptor type 6 (PTPN6) | 1.7 | Up |
| Signal transducer and activator of transcription 1, 91 kDa (STAT1) | 1.9 | Up |
| Signal transducer and activator of transcription 5A (STAT5A) | 1.6 | Up |
| **PPAR signaling pathway** | | |
| Angiopoietin-like 4 (ANGPTL4) | 6.9 | Down |
| Carnitine palmitoyltransferase 1A (liver) (CPT1A) | 1.8 | Down |
| Fatty acid binding protein 4, adipocyte (FABP4) | 1.8 | Down |
| Fatty acid binding protein 5 (psoriasis-associated) (FABP5) | 1.7 | Up |
| Glycerol kinase (GK) | 2.1 | Up |
| **Chemokine signaling pathway** | | |
| Cell division cycle 42 (CDC42) | 1.5901718 | Up |

FC, fold change; TNF, tumor necrosis factor.

Fig. 3. Diagrammatic representation of the interactions among genes within the cell adhesion molecule Kyoto Encyclopedia of Genes and Genomes pathway, with significantly upregulated genes in our experiments annotated. *Upregulated in porcine brain death model.
mediated toxicity [45], Jak-STAT signaling [46], peroxisome rejection, such as graft-versus-host disease [44], natural killer cell-rejection of renal grafts [42, 43], and research into anti-TNF agents have shown antibody-mediated rejection has been a target of anti-rejection mediation. The immune system is responsible for the acute and chronic inflammatory response to BD, and may explain organ-specific differences in transplantation outcomes after BD. However, variable results were obtained, with the former study did not show increased levels of cytokine mRNA between organ tissues [35], whereas the latter study showed a mixed picture of cytokine upregulation in the studied organs [36]. Whereas these studies have addressed targeted genes, we have sought to take a more global approach and use microarrays to identify a large numbers of genes simultaneously identify their molecular interaction and classify them to biological gene pathways. Perhaps most similar to our study is a comparison between BD and living donor swine that examined differences in apoptotic and protective gene expression patterns in multiple tissues, albeit after cold storage [37].

In our porcine model of BD, we found that 233 unique genes were noted to be significantly altered in those animals subject to brainstem herniation, when compared with those in a control group. These genes were classified into KEGG gene pathways that are related to immune modulation. The immune system is responsible for the acute and chronic rejection of organs, and cell adhesion molecule upregulation was hypothesized to be particularly affected. Cell adhesion molecules (CAMs) are glycoproteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis, and development of neuronal tissue. They have been shown to be integral in ischemia-reperfusion (IR) injuries in kidney tissue [39], and increased levels of CAMs have been associated with increased mortality in transplant recipients [40]. Several publications have examined treating donors to mitigate the IR injury, recently proposing that CAM-mediated IR injury can be treated with N-octanoyl dopamine. In this study, the researchers showed better early graft function and reduced acute rejection in renal allograft recipients after donors were treated with the drug [41]. These results were obtained in rats, and further investigation is warranted.

Ten additional gene pathways related to the immune system were significantly affected by the process of herniation in our study. Antigen processing and presentation has been associated with macrophage presence in rejected human renal allograft specimens [19], and antibody-mediated rejection has been a target of anti-rejection medications for years. Toll-like receptor-4 (TLR-4) has been increasingly recognized as playing a critical role in the pathogenesis of IR injury of renal grafts [42, 43], and research into anti-TNF agents have shown promise with regards to being protective against IR injury in animal models [21]. Additionally, we identified pathways associated with common immunologic processes affecting renal transplantation and rejection, such as graft-versus-host disease [44], natural killer cell-mediated toxicity [45], Jak-STAT signaling [46], peroxisome proliferator-activated receptor signaling [47], chemokine signaling, and allograft rejection. The limitations of this study include correlative data only. Though unable to prove causation, these data are a first step in identifying gene pathways that are altered in kidney tissue after BD. Additionally, there are no internal controls performed prior to herniation in each specimen, which potentially would aid in the delineation of the inflammatory response. Isoflurane anesthesia also may be considered to alter the inflammatory response. However, we attempted to control for this by administering this anesthetic to both the experimental and control animals, even though it was not needed for sedation or comfort in the BD group. It is also unclear as to the ultimate source of the inflammatory response to BD. Some investigators have postulated that neutrophils, platelets [48], and the nervous system [49] may be sources of the inflammatory response, but we were unable to address these concepts in the current study. Our intent was to address only the kidney, and future work would involve analysis of all transplantable organs, protein levels within organs, and circulating markers. In addition, expanding the animal model to include allotransplantation of organs into another subject would allow correlations between donor gene expression/biomarker patterns and recipient graft outcomes, the ultimate consequence of interest. This expansion would facilitate investigation of whether interventions in the donor can abrogate the inflammatory response and improve transplantation outcomes.

In this study, we addressed only the 6-hour time point after herniation. This time point was chosen for this initial study for several reasons. This time point is a practical surrogate for when actual interventions could begin to be carried out in a donor. In general, declaration of BD occurs 1–2 hours after the actual BD event, and then it requires several additional hours of obtaining authorization for donation and examining the donor before the organ procurement organization can begin to make interventions. A 6-hour time point marks the approximate start of donor management by the organ procurement organization, when interventions in the donor possibly could begin. Future studies would examine later time points, further characterizing the gene expression and gene pathways affected by BD and potentially guiding therapeutic interventions at these times. The raw data of the 6-hour time point can be found in GEO database (series accession number GSE94709) and is available for additional analyses and comparisons with current and future genomic datasets related to kidney injury or other kidney donor studies. Many studies have shown conflicting results in examination of the impact of duration of donor management [7, 50–52] and the best strategy for optimal duration of management is still under investigation. Later time points in a porcine model may help in determining kidney-specific genomic changes in examining duration of donor management.

Using a porcine model of brainstem herniation, we showed for the first time that multiple gene pathways associated with inflammation and organ rejection are altered in the donor after BD when compared with control animals. Building on this approach, new studies will generate data on additional time points with a goal to characterize potential biomarkers and gene pathways and identify the window of opportunity for organ management/procurement and. Animal models that correlate gene expression patterns in organs at the time of recovery with post-transplant outcomes would be essential in identifying appropriate targets in the DBD for future interventions. With the development of

### Table 3. Reverse transcriptase polymerase-chain reaction verification of specific genes in the cell adhesion pathway

| Gene name (gene symbol)                                      | Fold change | Directional change | p-Value |
|-------------------------------------------------------------|-------------|--------------------|---------|
| MHC class I antigen 1 (SLA-I)                               | 1.27        | Up                 | 0.06    |
| MHC class II DR-α (SLA-DR-A)                                | 1.31        | Up                 | 0.018   |
| MHC class II histocompatibility antigen SLA-DQA1 (SLA-DQA1) | 1.34        | Up                 | 0.05    |
| Integrin, β 2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 1.63 | Up                  | 0.003   |
| Integrin, β 8 (ITGB8)                                      | 1.83        | Up                 | 4.12E-06|
| Vascular cell adhesion molecule I (VCAM1)                  | 4.03        | Up                 | 7.93E-05|

The gene expression patterns in organs at the time of recovery with post-transplant outcomes would be essential in identifying appropriate targets in the DBD for future interventions.
valid animal models, possible interventions could be tested with little risk to transplantable human organs. Donor management after BD is one step in the process of organ donation in which these interventions could occur. This study begins to identify the underlying molecular mechanisms associated with this event, and aims to act as a first step towards targeting specific pathways that could optimize organs for successful transplantation.

Supplementary materials

To view supplementary material for this article, please visit https://doi.org/10.1017/ccts.2018.312

Acknowledgements

This paper was partially supported by NIH-NCATS grant no. ULI TR001414.

Disclosures

The authors have no conflicts of interest to declare. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

References

1. Rao PS, Ojo A. Organ retransplantation in the United States: trends and implications. Clinical and Transplantation 2008; 57–67.

2. Freitas MC. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry. Clinical and Transplantation 2011; 1–16.

3. Cooper DK, Novitzky D, Wichom WN. The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. Annals of the Royal College of Surgeons of England 1989; 71: 261–266.

4. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987; 43: 852–854.

5. Nijboer WN, et al. Effects of brain death on stress and inflammatory response in the human donor kidney. Transplantation Proceedings 2005; 37: 367–369.

6. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. American Journal of Transplantation 2009; 9: 899–997.

7. Iznierwicz A, et al. Duration of brain death and cold ischemia time, but not warm ischemia time, increases expression of genes associated with apoptosis in transplanted kidneys from deceased donors. Transplantation Proceedings 2011; 43: 2887–2890.

8. Kusaka M, et al. Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation 2000; 69: 405–410.

9. Olinga P, et al. The influence of brain death on liver function. Liver International 2005; 25: 109–116.

10. Dziodzio T, Biel M, Pratschke J. Impact of brain death on ischemic reperfusion injury in liver transplantation. Current Opinion in Organ Transplantation 2014; 19: 108–114.

11. Wilhelm MJ, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000; 102: 2426–2433.

12. Weiss S, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. American Journal of Transplantation 2007; 7: 1584–1593.

13. Pratschke J, et al. Accelerated rejection of renal allografts from brain-dead donors. Annals of Surgery 2000; 232: 263–271.

14. Leithead JA, et al. Hepatic ischemia reperfusion injury is associated with acute kidney injury following donation after brain death liver transplantation. Transplant International 2013; 26: 1116–1125.

15. Damman J, et al. Targeting complement activation in brain-dead donors improves renal function after transplantation. Transplant Immunology 2011; 24: 233–237.

16. Damman J, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 2011; 92: 163–169.

17. Hauser P, et al. Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Laboratory Investigation 2004; 84: 353–361.

18. McLean KM, et al. Glucocorticoids alter the balance between pro- and anti-inflammatory mediators in the myocardium in a porcine model of brain death, Journal of Heart and Lung Transplantation 2007; 26: 78–84.

19. Bergler T, et al. Infiltration of macrophages correlates with severity of allograft rejection and outcome in human kidney transplantation. PlaS One 2016; 11: e0156900.

20. Braza F, et al. Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nature Reviews Nephrology 2016; 12: 281–290.

21. Nagata Y, et al. Anti-TNF-alpha agent infiximab and splenectomy are protective against renal ischemia-reperfusion injury. Transplantation 2016; 100: 1675–1682.

22. Wang D, et al. Brief exercises affect gene expression in circulating monocytes. Scandinavian Journal of Immunology 2015; 82: 429–435.

23. Wu D, et al. Network analysis reveals roles of inflammatory factors in different phenotypes of kidney transplant patients. Journal of Theoretical Biology 2014; 362: 62–68.

24. Heemann UW, et al. Adhesion molecules and transplantation. Annals of Surgery 1994; 219: 4–12.

25. Venner JM, et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. American Journal of Transplantation 2015; 15: 1336–1348.

26. Shang D, et al. Profiling of mRNA and long non-coding RNA of urothelial cancer in recipients after renal transplantation. Tumour Biology 2016; 37: 12673–12684.

27. Baek A, Cho SR, Kim SH. Elucidation of gene expression patterns in the brain after spinal cord injury. Cell Transplantation 2017; 26: 1286–1300.

28. Israni AK, et al. Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation. American Journal of Kidney Diseases 2008; 52: 331–339.

29. Alakulppi NS, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004; 78: 1422–1428.

30. Park JY, et al. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans. Tissue Antigens 2004; 64: 660–666.

31. Goncalves-Primo A, et al. Investigation of apoptosis-related gene expression levels in preimplantation biopsies as predictors of delayed kidney graft function. Transplantation 2014; 97: 1260–1265.

32. Kaminska D, et al. Kidney ischemic injury genes expressed after donor brain death are predictive for the outcome of kidney transplantation. Transplantation Proceedings 2011; 43: 2891–2894.

33. Seek J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of National Academy of Sciences of the United States of America 2013; 110: 3507–3512.

34. Freeman TC, et al. A gene expression atlas of the domestic pig. BMC Biology 2012; 10: 90.

35. Barklin A, et al. Does brain death induce a pro-inflammatory response at the organ level in a porcine model? Acta Anesthesiologica Scandinavica 2008; 52: 621–627.

36. Skrabal CA, et al. Organ-specific regulation of pro-inflammatory molecules in heart, lung, and kidney following brain death. Journal of Surgical Research 2005; 123: 118–125.

37. Stiegler P, et al. Oxidative stress and apoptosis in a pig model of brain death (BD) and living donation (LD). Journal of Translational Medicine 2013; 11: 244.

38. Pratschke J, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. Journal of the American Society of Nephrology 2001; 12: 2474–2481.

39. Kusaka M, et al. Up-regulation of osteopontin, chemokines, adhesion molecule, and heat shock proteins in 1-hour biopsy from cardiac death donor kidneys. Transplantation Proceedings 2006; 38: 3347–3350.
40. Connolly GM, et al. Elevated soluble cellular adhesion molecules are associated with increased mortality in a prospective cohort of renal transplant recipients. BMC Nephrology 2011; 12: 23.

41. Spindler RS, et al. N-Octanoyl dopamine for donor treatment in a brain-death model of kidney and heart transplantation. Transplantation 2015; 99: 935–941.

42. Krichen H, et al. Toll-like receptor 4 and CD14 gene polymorphisms in Tunisian kidney transplantation. Transplantation Proceedings 2013; 45: 3472–3477.

43. Zhao H, et al. Role of toll-like receptor-4 in renal graft ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2014; 306: F801–F811.

44. Chen X, et al. Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation. European Journal of Medical Research 2016; 21: 38.

45. Kohei N, et al. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts. Kidney International 2016; 89: 1293–1306.

46. Baan CC, et al. Targeting JAK/STAT signaling to prevent rejection after kidney transplantation: a reappraisal. Transplantation 2016; 100: 1833–1839.

47. Kiss E, et al. Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. American Journal of Pathology 2010; 176: 2150–2162.

48. Stahel PF, et al. Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. Journal of Cerebral Blood Flow & Metabolism 2000; 20: 369–380.

49. Fluitner K, et al. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. Journal of Immunology 2014; 192: 2339–2348.

50. Muruve NA, et al. Effect of donor brain-death duration on graft outcome. Transplantation Proceedings 2001; 33: 2980–2981.

51. Blasco V, et al. Impact of intensive care on renal function before graft harvest: results of a monocentric study. Critical Care 2007; 11: R103.

52. Nijboer WN, et al. How important is the duration of the brain death period for the outcome in kidney transplantation? Transplant International 2011; 24: 14–20.